Molecular Mechanisms involved in Antibody-Dependent Enhancement of Dengue Virus Infection in Humans Jacky Flipse, Jan Wilschut, and Jolanda M. Smit Published in: Traffic (2013), 14(1): 25 – 35. Abstract Dengue is the most common arthropod-borne viral infection in humans with ~50 million cases annually worldwide.
Dengue is caused by a virus of the Flaviviridae family and there are four distinct, but closely related, serotypes of the virus that cause dengue (DENV-1, DENV-2, DENV-3 and DENV-4). Recovery from infection is believed to provide lifelong immunity against that serotype.
Jun 04, 2009 · Outbreaks of Dengue impose a heavy economic burden on developing countries in terms of vector control and human morbidity. Effective vaccines against all four serotypes of Dengue are in development, but population replacement with transgenic vectors unable to transmit the virus might ultimately prove to be an effective approach to disease suppression, or even eradication.
viruses, and Hepacivirus. Many members from the genus Flavivirus are arthropod-borne and cause significant human diseases, such as the 4 serotypes of dengue virus (DENV), West Nile virus (WNV), yellow fever virus (YFV), Japanese enceph-alitis virus (JEV), and tick-borne encephalitis virus (TBEV) (1).
Dengue virus (DENV) infections are expanding worldwide and, because of the lack of a vaccine, the search for antiviral products is imperative. Four serotypes of DENV are described and they all cause a similar disease outcome. It would be interesting to develop an antiviral product that can interact with all four serotypes, prevent host cell infection and subsequent immune activation. DENV ...
The virus that causes dengue is transmitted by mosquitoes. Dengue fever usually starts with a fever, joint pain, rash and nausea. Without treatment, the virus can cause damage to blood and lymph vessels and lead to dengue hemorrhagic fever, which is marked by difficulty breathing, bruising and bleeding from the nose, gums or under the skin.
Pharmacology: Pharmacodynamics: Mechanism of action: Dengvaxia contains live attenuated viruses. Following administration, the viruses replicate locally and elicit neutralizing antibodies and cell-mediated immune responses against the four dengue virus serotypes.
E gene sequences of dengue virus serotypes 1, 2, 3, or 4. Each CYD virus is cultured separately in Vero cells (African Green Monkey kidney) under serum-free conditions,
Sep 23, 2019 · Dengue Vaccine Globally. A vaccine to prevent dengue (Dengvaxia®) is licensed and available in some countries for people ages 9-45 years old. The World Health Organization recommends that the vaccine only be given to persons with confirmed prior dengue virus infection.
The senior health ministry official quoted above said that a team from Sun Pharma met CDSCO officials Monday for a detailed briefing on the “mechanism of action” of the drug. “Trials will explain better but the company cited that coronavirus and dengue-causing viruses behave similarly in the human body.